Hemogenyx enters collaboration agreement with Orgenesis

Biopharmaceutical group Hemogenyx has entered into a collaboration agreement with cell therapy outfit Orgenesis to further commercialise its humanised-mouse drug model.

Orgenesis inked the deal with Hemogenyx's Immugenyx subsidiary in order to gain access to its AHC products, a new type of humanised mouse with a functional 'human' immune system used for disease modelling and the development of drugs and cell therapies.

The Maryland-based biopharmaceutical company will advance the London-listed company a convertible loan of at least $1m for the right to market and serve as a distributor of Immugenyx products.

Immugenyx will retain exclusive rights to manufacture, make and supply hematopoietic chimera products to Orgenesis or its affiliates, which will pay Hemogenyx a royalty of 12% of net revenues generated from the technology.

Hemogenyx chief executive Dr Vladislav Sandler, said: "The commercial collaboration, license agreement and investment is an additional confirmation of the uniqueness and value of Immugenyx' AHC platform."

Earlier in the week, Hemogenyx reached a deal with industry giant Johnson and Johnson that will see the pair collaborate on research activities to be determined by a mutually approved research plan.

Immugenyx will own the humanised mouse model and grant Johnson and its affiliates a perpetual, irrevocable, non-exclusive, fully paid-up, transferable, worldwide, license to use the model for their own internal research and product development purposes.

As of 0840 BST, Hemogenyx shares had shot up 12.73% to 3.10p.